| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 401.25M | — |
| Operating expense | — | — |
| Net income | -4.89M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, AB3A.F returned -0.8% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | -15.6% |
| 1 year | -0.8% |
| 5 years | -75.8% |
| 10 years | -33.6% |
| All-time high | €147.00 (Jun 2024) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in AB3A.F would be worth today ›No. Sarepta Therapeutics, Inc. has not paid a dividend in the past 12 months.
Sarepta Therapeutics, Inc. is part of the Healthcare sector.
Sarepta Therapeutics, Inc. has a market cap of 1.64B EUR, based on the latest quote.
Sarepta Therapeutics, Inc. is expected to report earnings around Nov 4, 2026. That date is an estimate and has not been confirmed by the company.
